{"schema":"sb.node.v1","id":"sb:e/947dabec325310ef8dce80f1","kind":"entity","label":{"text":"car-t","locale":"en"},"identity":{"anchor":"label:en:car-t","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-10T15:54:56.699691+00:00","snapshot":"deploy 5dd6bfa537b0d111fd487bdb898acfd5f7a13cfd"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":105,"separatePublishers":38,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"measured","share":0.917,"named":11,"of":12,"basis":"receipts the entity graph keeps whose own headline names the subject, over all receipts it keeps for the subject (the door's measurement; the graph carries none of its own). Only the former are served"}},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-01-01","to":"2026-10-08","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.19: about 81% of mentions carry no typed assertion"]}},"dimensions":{"domains":["auto","precision_medicine"],"activeDays":33,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":11,"byKind":{"observation":11},"withheld":{"state":"withheld","count":1,"offTopic":1,"reason":"1 receipt not served: 1 off topic: the receipt's own headline does not name the subject (the document mentions it elsewhere, so it is counted in standing.evidence.supporting, but it is not a receipt about the subject)"},"items":[{"id":"sb:o/21bbc7fe0812af812ad13bfb","kind":"observation","label":"AllSci News · 2026-10-07 · Caribou Bio halts both CAR-T programs and launches sale process amid funding challenges","url":"https://allsci.com/news/biotech/caribou-biosciences-halts-both-car-t-programs-and/"},{"id":"sb:o/9cd75748d64d35bab296e0ef","kind":"observation","label":"Endpoints News · 2026-10-07 · CAR-T biotech Caribou weighs its options after struggling to find funding","url":"https://endpoints.news/car-t-biotech-caribou-weighs-its-options-after-struggling-to-find-funding/"},{"id":"sb:o/a3807745586cdf9681fea187","kind":"observation","label":"Denkstrom · 2026-10-07 · 17,7 Millionen Dollar für neue CAR-T-Studie","url":"https://denkstrom.org/artikel/17-7-millionen-dollar-fuer-neue-car-t-studie/"},{"id":"sb:o/792c6e77a6009a98b4c40805","kind":"observation","label":"Medical Daily · 2026-09-30 · Lupus Patients Stopped Every Immunosuppressant After One Off-the-Shelf CAR-T Dose in Small Trial, but Therapy Remains Experimental","url":"https://www.medicaldaily.com/lupus-car-t-prula-cel-immunosuppressant-free-remission-trial-479286"},{"id":"sb:o/c74a2c033422c1fe69ab92eb","kind":"observation","label":"AllSci News · 2026-09-30 · IASO Bio’s BCMA/GPRC5D dual-targeted CAR-T RD140 shows 88.9% response rate in Phase I","url":"https://allsci.com/news/biotech/car-t-myeloma-response-iaso-bios-dual-targeted/"},{"id":"sb:o/8dd25455d7d915559aa1feae","kind":"observation","label":"PR Newswire · 2026-09-27 · 2026 IMS | IASO Bio Presented First-in-Human Data of BCMA-Targeted In Vivo CAR-T Cell Therapy IASO206","url":"https://www.prnewswire.com/news-releases/2026-ims--iaso-bio-presented-first-in-human-data-of-bcma-targeted-in-vivo-car-t-cell-therapy-iaso206-302890813.html"},{"id":"sb:o/39d2aab2e4b05746d86fe383","kind":"observation","label":"BioPharma Dive · 2026-09-15 · Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing","url":"https://www.biopharmadive.com/news/cellectis-restructure-in-vivo-gene-editing-allogeneic-heart-disease/830281/"},{"id":"sb:o/6501f059007d830adf3be1d8","kind":"observation","label":"Fierce Biotech · 2026-09-07 · BrainChild Bio masterminds $116M series A for CAR-T's pivotal push in pediatric brain cancer","url":"https://www.fiercebiotech.com/biotech/brainchild-bio-masterminds-116m-series-pivotal-push-pediatric-brain-cancer"},{"id":"sb:o/26d30dc65e6c8031d20e7459","kind":"observation","label":"J Gastroenterol · 2026-09-07 · A PRK-armed oncolytic adenovirus drives calreticulin exposure for dendritic cell licensing to prime antitumor CD8⁺ T cells and synergizes with anti-PD-1 or CAR-T therap…","url":"https://doi.org/10.1007/s00535-026-02513-2"},{"id":"sb:o/018f84c0abe3ea7252bb4adb","kind":"observation","label":"STAT News · 2026-09-05 · STAT+: We’re reading about a Bristol CAR-T trial pause, Pfizer offloading a shelved candidate, and more","url":"https://www.statnews.com/pharmalot/2026/09/04/pharmalittle-bristol-car-t-trial-pause-pfizer-offloads-shelved-candidate/?utm_campaign=rss"}],"cursor":"c1.eyJpZCI6InNiOmUvOTQ3ZGFiZWMzMjUzMTBlZjhkY2U4MGYxIiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTEwVDE1OjU0OjU2LjY5OTY5MSswMDowMCJ9","order":"newest first; we keep the 11 newest receipts for this entity whose own headline names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with t-cell (48 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/f1006b5a34579889c60a7077"},{"kind":"relation","label":"co-mentioned with fda (44 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/1dcae36ceb1eb26d2b93c890"},{"kind":"relation","label":"co-mentioned with studie (37 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/45aea63d43d3371626b1cc50"},{"kind":"relation","label":"co-mentioned with immunotherapy (32 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/3764987e7a269b4f80c3ecaa"},{"kind":"relation","label":"co-mentioned with clinical trial (29 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/a4cf05918a3f17e26dabb7ce"},{"kind":"relation","label":"co-mentioned with car t-cell (27 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/9c5a4b17e506065679365656"},{"kind":"relation","label":"co-mentioned with clinical trials (25 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/5211636232fe1e5916b3d13e"},{"kind":"relation","label":"co-mentioned with ai (23 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/52b8928a10471df1efeff232"},{"kind":"relation","label":"co-mentioned with solid tumors (22 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c397c946ab2459a73f1549f7"},{"kind":"relation","label":"co-mentioned with united states (18 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/f2f4fb5c47394e48a0a355bc"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/947dabec325310ef8dce80f1","mcp":"traverse {\"id\":\"sb:e/947dabec325310ef8dce80f1\"}","page":"/entity/car-t/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/947dabec325310ef8dce80f1\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/947dabec325310ef8dce80f1\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/947dabec325310ef8dce80f1\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/947dabec325310ef8dce80f1\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}